Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Your guide to how to safely thaw and cook your Thanksgiving turkey this year, according to experts - 2Rebecca Gayheart on her 'very complicated' relationship with Eric Dane: 'I am always going to want the best for him'
- 310 Delectable Specialty Mixed drinks
- 4Figure out How to Reveal Stowed away Open Record Rewards
- 5Indoor Drinking Fountains: Famous Home Advancements during the Pandemic
- Book excerpt: "Enough" by Dr. Ania Jastreboff and Oprah Winfrey
- Find Your Ideal Tea: Six Particular Assortments
- Humpback whale stranded on Germany's Baltic coast frees itself
- US EPA will reassess safety of herbicide paraquat, says its chief
- Pick Your Favored sort of cooking
- The Best Business visionaries Under 30
- 5 Worldwide Road Food varieties You Should Attempt
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- Top Fascinating Organic products: Which One Might You Want to Attempt?
